Clinical Trial Update: Icotinib for Completed Resected IB NSCLC With EGFR Mutation [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 trial of icotinib for resected Stage IB non-small cell lung cancer with EGFR mutation, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Stage Ib Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Lung Neoplasms, Squamous Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-09-25